These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8666016)

  • 21. The action of prolyl-leucyl-glycinamide (PLG) on the nigrostriatal pathway of the rat.
    Pereira JS; Andrade LA; Bertolucci PH; Lima JG; Ferraz HB
    Arq Neuropsiquiatr; 1990 Jun; 48(2):156-60. PubMed ID: 1979732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of the mesolimbic dopaminergic system by beta-endorphin-(1-27) as assessed by microdialysis.
    Spanagel R; Herz A; Shippenberg TS
    Eur J Pharmacol; 1991 Aug; 200(2-3):319-24. PubMed ID: 1782993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blockade of brain dopamine receptors antagonizes the anti-immobility effect of MIF-1 and Tyr-MIF-1 in rats.
    Pulvirenti L; Kastin AJ
    Eur J Pharmacol; 1988 Jul; 151(2):289-92. PubMed ID: 2901971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurologically active peptides.
    Barbeau A; Gonce M; Kastin AJ
    Pharmacol Biochem Behav; 1976; 5(Suppl 1):159-63. PubMed ID: 13415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of intragastric administration of beta-endorphin on thyrotropin-releasing hormone and somatostatin release into gastric lumen of rats.
    Konagaya T; Kusugami K; Yamamoto H; Nishio Y; Kaneko H; Nagai H; Mitsuma T
    J Gastroenterol; 1998 Feb; 33(1):27-31. PubMed ID: 9497218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-opiate effects of neuropeptides derived from beta-endorphin.
    De Wied D; Van Ree JM
    Pol J Pharmacol Pharm; 1987; 39(5):623-32. PubMed ID: 2976164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pituitary proopiomelanocortin-derived peptides and hypothalamus-pituitary-interrenal axis activity in gilthead sea bream (Sparus aurata) during prolonged crowding stress: differential regulation of adrenocorticotropin hormone and alpha-melanocyte-stimulating hormone release by corticotropin-releasing hormone and thyrotropin-releasing hormone.
    Rotllant J; Balm PH; Ruane NM; Pérez-Sánchez J; Wendelaar-Bonga SE; Tort L
    Gen Comp Endocrinol; 2000 Aug; 119(2):152-63. PubMed ID: 10936035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of chronic treatment with morphine on the binding of 3H-N-n-propylnorapomorphine to striatal membranes of rats: influence of prolyl-leucyl-glycinamide.
    Das S; Bhargava HN
    Pharmacology; 1985; 31(5):241-7. PubMed ID: 2866551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of endogenous opioid peptides on TRH release from rat stomach in vitro.
    Mitsuma T; Hirooka Y; Nakada K; Nomura A; Nogimori T
    Endocrinol Exp; 1989 Mar; 23(1):11-6. PubMed ID: 2565806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thyrotropin-releasing hormone reduces the plasma levels of beta-endorphin-like immunoreactivity in rats.
    Mitsuma T; Nogimori T; Sun DH; Chaya M
    Exp Clin Endocrinol; 1987 Mar; 89(1):55-60. PubMed ID: 2954835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of neuropeptides on discrete-trial conditioned avoidance responding.
    Luttinger D; Nemeroff CB; Prange AJ
    Brain Res; 1982 Apr; 237(1):183-92. PubMed ID: 6176291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurotensin-induced antinociception in mice: antagonism by thyrotropin-releasing hormone.
    Osbahr AJ; Nemeroff CB; Luttinger D; Mason GA; Prange AJ
    J Pharmacol Exp Ther; 1981 Jun; 217(3):645-51. PubMed ID: 6112261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic melanocyte stimulating hormone release-inhibiting factor (MIF). Part III: effect of L-prolyl-N-methyl-D-leucyl-glycinamide and MIF on biogenic amine turnover.
    Pugsley TA; Lippmann W
    Arzneimittelforschung; 1977; 27(12):2293-6. PubMed ID: 23796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopamine and melatonin in the nucleus accumbens may be implicated in the mode of action of antidepressant drugs.
    Durlach-Misteli C; Van Ree JM
    Eur J Pharmacol; 1992 Jun; 217(1):15-21. PubMed ID: 1397023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in the behavioural response to a TRH analogue following chronic amitriptyline treatment and repeated electroconvulsive shock in the rat.
    Bennett GW; Green AR; Lighton C; Marsden CA
    Br J Pharmacol; 1986 May; 88(1):129-39. PubMed ID: 3085759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuropharmacological studies with thyrotropin releasing hormone (TRH) and other hypothalamic hormones.
    Kruse H
    Naunyn Schmiedebergs Arch Pharmacol; 1977; 297 Suppl 1():S61-2. PubMed ID: 16226
    [No Abstract]   [Full Text] [Related]  

  • 37. Discovery of a dual action first-in-class peptide that mimics and enhances CNS-mediated actions of thyrotropin-releasing hormone.
    Scalabrino GA; Hogan N; O'Boyle KM; Slator GR; Gregg DJ; Fitchett CM; Draper SM; Bennett GW; Hinkle PM; Bauer K; Williams CH; Tipton KF; Kelly JA
    Neuropharmacology; 2007 Jun; 52(7):1472-81. PubMed ID: 17418282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peptides and thermoregulation.
    Yehuda S; Kastin AJ
    Neurosci Biobehav Rev; 1980; 4(4):459-71. PubMed ID: 6110198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of the opioid receptor types mediating beta-endorphin-induced alterations in dopamine release in the nucleus accumbens.
    Spanagel R; Herz A; Shippenberg TS
    Eur J Pharmacol; 1990 Nov; 190(1-2):177-84. PubMed ID: 1981749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of the tripeptides TRH, MIF and MAF on the cerebral dopaminergic system.
    Klusha B; Georgiev V; Petkov V; Markovska V
    Acta Physiol Pharmacol Bulg; 1983; 9(2):14-9. PubMed ID: 6140814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.